Nilotinib

(Tasigna)

Nilotinib

Drug updated on 9/14/2023

Dosage FormCapsules (oral; 50 mg, 150 mg, and 200 mg)
Drug ClassKinase Inhibitor
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
  • For the treatment of adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.
  • For the treatment of pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.

Product Monograph / Prescribing Information

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Chronic myeloid leukemia, version 2.2021.2020Journal of the National Comprehensive Network of Cancer
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia.2020British Journal of Haematology
Acute lymphoblastic leukemia, version 2.2021.2020Journal of the National Comprehensive Network of Cancer